A Phase I Study of Sunitinib and Rapamycin [sirolimus] in Advanced Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Sirolimus (Primary) ; Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms SU/Rapamycin
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 21 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.